Danaher Gestione
Criteri Gestione verificati 3/4
Danaher Il CEO è Rainer Blair, nominato in Sep2020, e ha un mandato di 5.67 anni. la retribuzione annua totale è $ 23.80M, composta da 5.9% di stipendio e 94.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.01% delle azioni della società, per un valore di $ 12.30M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 16 anni.
Informazioni chiave
Rainer Blair
Amministratore delegato
US$23.8m
Compenso totale
| Percentuale dello stipendio del CEO | 5.88% |
| Mandato del CEO | 5.7yrs |
| Proprietà del CEO | 0.01% |
| Durata media del management | 2.3yrs |
| Durata media del Consiglio di amministrazione | 16yrs |
Aggiornamenti recenti sulla gestione
Recent updates
DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple
Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.Danaher Q1 2026 Earnings Update
Apr 22
Danaher Corporation (DHR): The Life Sciences Titan and the "Diagnostic Diversification" Shift
Danaher Corporation (DHR) , the global life sciences and diagnostics innovator, enters Tuesday, April 21, 2026 , following a mixed but resilient first-quarter earnings performance. Trading at $195.60 USD —a marginal 0.05% gain in a volatile post-earnings session—the stock is seeking firm support above its recent low of $181.01.DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple
Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple
Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple
Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple
The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple
Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook
Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple
Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple
Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers
Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty
Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside
Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds
Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher
Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.Advanced Diagnostics And Personalized Therapies Will Expand Global Markets
Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings
Aug 01
Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?
Jul 12Is Danaher (NYSE:DHR) A Risky Investment?
May 22Danaher Corporation's (NYSE:DHR) Popularity With Investors Is Clear
May 07Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Mar 31Danaher: Near 5-Year Low Is A Great Entry Point
Mar 22Danaher: Self-Inflicted Pessimism?
Feb 17Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued
Jan 15Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Jan 06Danaher: A Resilient And Solid Company With Growth Potential
Dec 10Understanding Danaher's Cautiousness
Oct 25Danaher Q3 Preview: Market Share Gains In Molecular Testing
Sep 25Danaher: Lofty Price, Bright Future
Aug 22Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 27 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$24m | US$1m | US$4b |
| Sep 26 2025 | n/a | n/a | US$4b |
| Jun 27 2025 | n/a | n/a | US$3b |
| Mar 28 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$22m | US$1m | US$4b |
| Sep 27 2024 | n/a | n/a | US$4b |
| Jun 28 2024 | n/a | n/a | US$4b |
| Mar 29 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$1m | US$4b |
| Sep 29 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$20m | US$1m | US$6b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jul 01 2022 | n/a | n/a | US$6b |
| Apr 01 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$17m | US$1m | US$5b |
| Oct 01 2021 | n/a | n/a | US$6b |
| Jul 02 2021 | n/a | n/a | US$5b |
| Apr 02 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$10m | US$949k | US$4b |
| Oct 02 2020 | n/a | n/a | US$3b |
| Jul 03 2020 | n/a | n/a | US$3b |
| Apr 03 2020 | n/a | n/a | US$3b |
| Dec 31 2019 | US$7m | US$840k | US$2b |
Compensazione vs Mercato: La retribuzione totale di Rainer ($USD 23.80M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 14.60M ).
Compensazione vs guadagni: La retribuzione di Rainer è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Rainer Blair (61 yo)
5.7yrs
Mandato
US$23,795,280
Compensazione
Mr. Rainer M. Blair serves as an Independent Non-Executive Director at Nestlé S.A. since April 20, 2023. He serves as President, Chief Executive Officer and Director at Danaher Corporation since September...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Chairman | 43.3yrs | Nessun dato | 5.97% $ 7.4b | |
| President | 5.7yrs | US$23.80m | 0.0099% $ 12.3m | |
| Co-Founder & Director | 43.3yrs | Nessun dato | 4.77% $ 5.9b | |
| Senior VP & Chief Science Officer | 5.4yrs | US$6.24m | 0.0011% $ 1.4m | |
| Executive Vice President | less than a year | US$7.97m | 0.0040% $ 5.0m | |
| Executive VP of Biotechnology Group & CEO of Cytiva | 2.3yrs | US$11.26m | 0.00059% $ 731.4k | |
| Executive Vice President of Diagnostics Platform | 1.8yrs | US$11.30m | 0.00080% $ 991.7k | |
| Executive VP & CFO | less than a year | Nessun dato | 0.0011% $ 1.3m | |
| VP & Chief Accounting Officer | 4.3yrs | Nessun dato | 0.00098% $ 1.2m | |
| Chief Technology & AI Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Legal Officer | less than a year | Nessun dato | Nessun dato |
2.3yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di DHR è considerato esperto (durata media dell'incarico 2.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Chairman | 43.3yrs | Nessun dato | 5.97% $ 7.4b | |
| President | 5.7yrs | US$23.80m | 0.0099% $ 12.3m | |
| Co-Founder & Director | 43.3yrs | Nessun dato | 4.77% $ 5.9b | |
| Independent Director | 27.3yrs | US$351.03k | 0.012% $ 14.9m | |
| Independent Director | 22.8yrs | US$351.03k | 0.0058% $ 7.2m | |
| Independent Director | 17.3yrs | US$373.53k | 0.0023% $ 2.9m | |
| Independent Director | 9.3yrs | US$351.03k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.1yrs | Nessun dato | Nessun dato | |
| Lead Independent Director | 20.4yrs | US$413.53k | 0.0031% $ 3.8m | |
| Member of Scientific Advisory Board | 5.1yrs | Nessun dato | Nessun dato | |
| Independent Director | 14.7yrs | US$379.53k | 0% $ 0 | |
| Independent Director | 5yrs | US$378.53k | 0% $ 0 |
16.0yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di DHR è composto da personale esperto e esperto (durata media dell'incarico 16 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 16:15 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2026/03/27 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Danaher Corporation è coperta da 43 analisti. 21 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Eade | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |